Reason for request
Inclusion on the list of medicines refundable by National Health Insurance and approved for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of ZYTIGA is substantial. |
Clinical Added Value
| moderate |
ZYTIGA provides a moderate improvement in actual benefit (level III) in terms of efficacy and tolerance in the treatment of metastatic castration-resistant prostate cancer which progresses during or after docetaxel therapy. |
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
5Nxu1ZBTEXavzLTG
